IVIG to SCIG Switch in CIDP & MMN Patients: Improved Tolerability and Patient Satisfaction

Eight consecutive patients on long-term, hospital-based intravenous immunoglobulin (IVIG) therapy to treat chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (n=4) and multifocal motor neuropathy (MMN) (n=4) were switched to home-based subcutaneous immunoglobulin (SCIG).

Biosimilars: The Race for Approval

As the approval of biosimilars looms, debate continues over whether they should be substituted for biopharmaceuticals, how to legislate them and how they should be named.

Exploring the Power of IVIG

Clinical studies using intravenous immune globulin therapy are breaking new ground when it comes to treating chronic disease; promising results are being seen in patients suffering from Alzheimer’s, autism and even diabetes.

Immune Globulin: Controlling Supply and Demand

While the healthcare industry is currently experiencing an oversupply of the lifesaving immune globulin therapy, with demand growing at 6 percent to 8 percent a year, is it possible another shortage looms large?

Subcutaneous Immune Globulin: New Therapeutic Uses Beyond Primary Immunodeficiency?

While the intravenous route has been the standard method of IG therapy for autoimmune and other neuromuscular disorders, recent studies show that the subcutaneous route is both as effective and more preferred by patients.

FDA Approves Baxter’s HYQVIA for Treatment of PI

The U.S. Food and Drug Administration has approved HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency.

Rare Adverse Effects of Human Immunoglobulin Therapy

Less-common adverse reactions to IG therapy are rare, but they are more severe.

Single-Dose IVIG Results in Early Improvements in Sepsis Patients

A recent study conducted in Japan showed significant early post-administration improvements in sepsis patients who were given a single-dose administration of intravenous immune globulin (IVIG).

IVIG in Combination with Corticosteroids Reduces Morbidity and Mortality in Toxic Epidermal Necrolysis

Low-dose intravenous immune globulin added to a course of corticosteroids has been found to be superior to corticosteroid therapy alone in resolving toxic epidermal necrolysis and reducing associated mortality risk.

Dermatomyositis with Isolated Severe Skin Lesions Responds to IVIG Therapy

Investigators concluded that IVIG may be an effective and safe treatment for DM with isolated skin involvement.